Inhibition of estrogen-induced increases in uterine guanosine 3',5'-cyclic monophosphate levels by inhibitors of protein and RNA synthesis

Publisher Website
Google Scholar
Abstract
Uterine cyclic[c]GMP levels are elevated significantly from 2-12 h after a single injection of estradiol-17.beta. or diethylstilbestrol to mature, ovariectomized or immature rats. cGMP accumulation is greater in endometrial- than myometrial-enriched uterine tissue. The estrogen-induced increase in cGMP can be prevented by administration of the protein synthesis inhibitors, cycloheximide and puromycin, or by relatively large doses of the RNA synthesis inhibitor, actinomycin D, but not by the muscarinic antagonist, atropine. The requirement for a protein with a relatively rapid rate of turnover is suggested by the demonstration that cycloheximide, when administered after estrogen, can within a 3-h period restore the estrogen-elevated levels of cGMP to those of the non-estrogen-treated tissue.